Skip to main content

HT-1080 Cell Line

The HT-1080 cell line was taken from the connective tissue of a 35-year-old Caucasian male with fibrosarcoma. HT-1080 cells are tumorigenic and have modal chromosome number of 46. The HT-1080 cell line has epithelial morphological characteristics with culturally adherent properties. It is suitable for transfection, and an HT-1080 transfection reagent is available here through Altogen Biosystems. Transfection of HT-1080 cells can be used to study connective tissue cancers. HT-1080 cells express oncogene N-ras and are susceptible to Human poliovirus 1, Feline leukemia virus, vesicular stomatitis virus, and RD-114 feline virus.

Comments

Post a Comment

Popular posts from this blog

Xenograft Models and Cancer Studies with Altogen

Altogen Biosystems is a recognized manufacturer and laboratory for biological laboratories. Custom research opportunities and additional preclinical items include xenografts, drug testing, 28-day generation of stably-transfected cells, liposome encapsulation and more. Dedicated to assisting laboratories with cutting-edge and excellent services, Altogen Biosystems endeavors to improve modern laboratory technologies. Visit Altogen for xenograft models and assorted products to assist in cancer studies and preclinical laboratory research.
Post a Comment
Read more

HT-1080 Transfection Reagent (Fibrosarcoma Cells)

The HT-1080 cell line comes from tumorigenic connective tissue originally removed from a 35-year-old male Caucasian patient with fibrosarcoma in 1972. These cells have a susceptibility to an assortment of viruses such as the RD-114 feline virus, polio, vesicular stomatitis virus and feline leukemia virus. These cells are used in research involving connective tissue cancer. Altogen Biosystems  facilitates these research studies by manufacturing an HT-1080 transfection reagent for fibrosarcoma cells. The reagent has a high transfection efficacy for siRNA delivery.  Transfection Reagent for HT-1080 Cells (Fibrosarcoma Cells, CCL-121)
Read more

Drug Development and Fibrosarcoma Studies with HT-1080 Cells

Cancer of connective tissue can take a variety of forms, each requiring its own specific research for drug development and understanding proliferation pathways. Fibrosarcomas, which are cancers of fibrous connective tissue characterized by immature fibroblasts, affect human infants and middle-aged males. Derived in 1972, the HT-1080 cell line can be used as a testing ground for drug research and a model for fibrosarcoma research involving genetic screening. Transfection of siRNA sequences, essential for RNAi technology, can be accomplished through state-of-the-art lipid transfection reagents , ensuring that the cells give realistic responses that can inform drug development. HT-1080 cells, though susceptible to a variety of viruses, can still be useful tools for preclinical research specific to fibrosarcomas.
Post a Comment
Read more